C-NTUQGeron
telomerase inhibition
modulating
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-NTUQ
C-NTUQC-NTUQtelomerase inhibition
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Welcome back to Stock Market Analyst! In this episode, I reveal my latest long‑term options play on Geron Corp (GERN) — a clinical‑stage biopharma innovator targeting hematologic cancers. I’ve taken positions in Jan 2027 LEAP call options at the $2.50 and $3.00 strikes, aiming for a potential 5x–10x return if Geron’s growth story unfolds as expected. #GERNLEAP #GeronCorp #biotechstocks #optionstrading #LEAPoptions #RYTELO #stockmarketanalyst #investment strategy #FDAapproval #biopharmagrowth #Geronstockanalysis We’ll explore Geron’s biotech roadmap, including the RYTELO® launch, Phase 3 IMpactMF trial progress, and CEO Harout Semerjian’s commercialization strategy. You’ll see how strong revenue momentum, solid cash reserves, and expanding market potential could reshape the company’s valuation. #GERNLEAP #GeronCorp #biotechstocks #optionstrading #LEAPoptions #RYTELO #stockmarketanalyst #investment strategy #FDAapproval #biopharmagrowth #Geronstockanalysis #2027 I’ll also break down
Welcome back to Griffonomics, where we conduct financial investigations to define the risk before we look at the reward. Today, we’re unmasking the "Commercial Inflection" transformation of Geron—analyzing why Harout Semerjian is "burning the ships" of traditional sales teams to build a digital marketing powerhouse and whether the massive $401 million cash war chest is proof that Geron has finally found the ultimate compounding engine for blood cancer. The Risk: We analyze the "Salvage Therapy Trap"—examining why prescribers are relegating Rytelo to third-line usage despite NCCN guidelines and if the flat $48 million Q4 revenue represents a structural floor or a terminal ceiling. We detail the "GTN Margin Squeeze," investigating how 340B pricing and GPO contracts are projected to push revenue deductions into the 20% range in 2026. We examine the "Catalyst Gap," analyzing the difficult "Overall Survival" endpoint in the IMpactMF trial and the risk of waiting until 2028 for final data.
அஜர்பைஜானி்ல் பேயாட்டம் Iran RaisI Ghost-உள்ளே குதித்த RUSSIA Drone Geron -INDIA SIGN For KHAMENEI Azerbaijan says two people have been injured after Iranian drones and missiles fell near an international airport. It happened in the exclave of Nakhchivan. Azerbaijan has summoned the Iranian ambassador and says it reserves the right to retaliate. NEW VIDEO: Israeli F-35 shoots down Iranian fighter jet over Tehran India signs condolence book at Iranian embassy India condoles death of Kamini December 28th Kamini martyrdom - India takes important decision on sixth day Foreign Secretary Vikram Misri signs Fox News confirms that more than 650 US military personnel have been killed in Iran's IRGC retaliation. #Azerbaijan #Iran #Israel #drones #nakhchivan #irannews #irgc #operationtruepromise4 #650casualties #700drones #tehran #israel #hezbollah #haifa #lebanon #uae #bahrain #cyprus #westasia #iranisraelwar #breakingnews #iranazerbaijan #globalconflict #firstpost #newslive #worldne
Annie Enriquez-Geron, general secretary PSLINK, speaks to UNISON conference. PSLINK is a confederation of public sector unions of Philippine government employees from different national government agencies, state universities and colleges, local government units, government-financial institutions, health, teachers, and special sectors
Marjorie Taylor Greene loves to show everyone how uneducated she is, and during a rant on social media recently she put her ignorance on full display by calling for the judge in Trump's New York fraud trial to be stripped naked and thrown out of his position. Specifically, Greene called for the judge to be "disrobed," but that word actually means to strip and is not a legal term for removing a judge. This is the woman who wants to be our next Secretary of Homeland Security, as Ring of Fire's Farron Cousins explains. Link - https://www.mediaite.com/trump/huh-marjorie-taylor-greene-calls-for-judge-in-trump-civil-case-to-be-disrobed/ Check out our merch by visiting our store: https://www.buyrof.com/ Subscribe to our podcast: http://www.ROFPodcast.com Become a member today!: https://www.youtube.com/channel/UCYWIEbibRcZav6xMLo9qWWw/join Support us by becoming a monthly patron on Patreon, and help keep progressive media alive!: https://www.patreon.com/TheRingofFire Spread the word! L
VUNNY MORETO, Our SECRETARY! | SSG's REELTOK: Short Conversations - FINALE EPISODE: Sanggunian Ng ISANGgunian (PART 16/18) 🌾 Vunnylyn Y. Moreto Secretary SSG Batch '22 - '23 We started this journey with nothing but our genuine intent to serve and now that we have arrived at the end of the road, we’d like to serve one last time, not as outgoing leaders but as future guides! Watch as the student-leaders share their positions about their positions in the special last episode of SSG’s REELTOK: Short Conversations! Today’s Theme: “Sanggunian Ng ISANGgunian” The Supreme Student Government (SSG) interviewed the elected and assigned SSG Officers of School Year 2022 to 2023 about Today's Top Picks! Today's Top Picks are presented by the incoming Supreme Secondary Learner Government (SSLG). 🌾Why did you run or accept the position you currently hold? 🌾Can you elaborate on how you practice your duties and responsibilites? 🌾During the whole school year, what are some of your notable achieve
The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat sodium in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and preliminary clinical activity of the R2PD of imetelstat sodium in combination with ruxolitinib in participants with MF in Part 2.
The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.
Dr.Geron talk about lingual bracket treatment- "customized bracket positioning, customized brackets, it’s much much more easy than before, I don’t think it’s not a difficult technique now." eBrace invited Dr. Geron, the President of the Israel Orthodontic Society (IOS), the Secretary and founding member of WSLO (world society of Lingual Orthodontics) to talk about it.
The purpose of this study is to evaluate the efficacy and safety of imetelstat sodium in transfusion-dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to erythropoiesis-stimulating agent (ESA) treatment in Phase 2 study and to compare the efficacy, in terms of red blood cell (RBC) transfusion independence (TI), of imetelstat sodium to placebo in transfusion-dependent participants with low or intermediate-1 risk MDS that is relapsed/refractory to ESA treatment in Phase 3 study. A separate Ventricular Repolarization Substudy (QTc Substudy) will evaluate the effect of imetelstat sodium on ventricular repolarization. An Extension Phase has been included to allow continued treatment for those participants who are benefitting from imetelstat sodium and to continue to evaluate the long-term safety, overall survival (OS), and disease progression, including progression to acute myeloid leukemia (AML) in transfusion-dependent participants with low or immediate-1 risk MDS that is relapsed/refractory to ESA treatment.
President Benigno S. Aquino III appointed former Deputy Executive Secretary Ronaldo Geron as the new chief of the Bureau of Immigration. Geron took his oath of office yesterday, January 6. Latest global reports, balanced, up-to-date. It brings to fore EBC's rich international scope. Visit our website at: http://www.eaglenews.ph Follow us on Twitter at: http://www.twitter.com/eaglenewsph Like us on Facebook: http://www.facebook.com/EagleNewsPH
The purpose of this study is to evaluate the efficacy and safety of 2 dose regimens of imetelstat in participants with intermediate-2 or high-risk myelofibrosis (MF) whose disease is relapsed after or is refractory to Janus Kinase (JAK) inhibitor treatment. Key secondary endpoint includes overall survival.
Interview with a lawyer. Joseph Geron - De. Chairman of the Union of Jurists in Bulgaria, deputy. President of the International Association of Lawyers - Democrats, President of the National Association of Mediators, a longtime member of the Executive Board and Chief Secretary and now chairman of the legal committee and attorney OBJ, a member of the Spiritual Israelite Council in Bulgaria on the occasion of the upcoming Passover holiday - March 2013.
One of the speakers at the BLOS Masters in Lingual meeting is Dr Geron. Dr. Geron is a specialist in Orthodontics and Dentofacial Orthopedics. She received her DMD and Msc degrees from the Hebrew University Hadassah School of Dental Medicine, Jerusalem, in 1993. She maintains a private practice limited to orthodontics, Emphasizing Lingual and adult Orthodontics and is Director of Lingual Orthodontics in the international postgraduate orthodontic program in Tel-Aviv University and Tel-Hashomer Hospital, IDF, Israel. Dr. Geron is currently the president of the Israel Orthodontic Society (IOS), the Secretary and founding member of WSLO (world society of Lingual Orthodontics), Examiner of the Israeli Dental Association Scientific Council-Orthodontic Examination Committee, Reviewer for the American Journal of Orthodontics and Dentofacial Orthopedics and for the Angle Orthodontics. Dr. Geron was the founder and the editor of the Journal of the Israel Orthodontic Society (JIOS) and the fo
This pilot clinical trial studies how well imetelstat sodium works in treating participants with primary or secondary myelofibrosis and other myeloid malignancies. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
http://rtvm.gov.ph Rizal Hall, Malacañang July 8, 2010 Among those sworn in before the President were retired military officer Gen. Jose Angel Honrado who was appointed as the new General Manager of the Manila International Airport; former LTO Tarlac Chief of Registration Officer Virgie Torres as the new Assistant Secretary of the Department of Transportation and Communications (DOTC) and concurrent Chief of the Land Transportation Office (LTO). Also appointed were Ma. Lourdes Ong who will act as Presidential Assistant I with the rank of Undersecretary in the Office of the Special Assistant to the President; Susan Reyes as Assistant Executive Secretary for the Socials Secretary's Office; Rico Puno as Undersecretary for Peace and Order of the Department of the Interior and Local Government (DILG) and Eric Gosengfiao as Deputy Director General of the National Intelligence Coordinating Agency. The President also administered the oath to lawyers Jose Amor Amorado as Senior Deputy Executive
A hearing for a former New Mexico Secretary of State accused of wrongdoing will continue Wednesday morning. Rebecca Vigil-Geron and three co-defendants are accused of misusing millions of federal voter education dollars while on the job.
This is a phase II open-label study of single agent imetelstat in patients with essential thrombocytopenia or with polycythemia vera who have failed or are intolerant to at least one prior therapy, or who refuse standard therapy.
This is an open label Phase II study to determine the rate of improvement in response of patients with previously treated multiple myeloma to imetelstat alone or in combination with lenalidomide maintenance therapy. This study will include multiple myeloma patients who either have achieved disease stabilization or who have achieved at least a partial response (PR) but failed to achieve a complete response (CR) after cytoreductive therapy for multiple myeloma; ie, have detectable but non-progressing disease and will most likely relapse.
The purpose of this study is to evaluate the efficacy and safety of treatment with imetelstat + paclitaxel (with or without bevacizumab) versus paclitaxel (with or without bevacizumab) alone for patients with locally recurrent or metastatic breast cancer who have not received chemotherapy or have received one non-taxane based chemotherapy for metastatic breast cancer.
The purpose of this is to evaluate the efficacy and safety of imetelstat (GRN163L) as maintenance therapy for patients with advanced stage NSCLC who have not progressed after 4 cycles of platinum based therapy. Participants will be randomized in a 2:1 ratio to imetelstat + standard of care versus standard of care alone. Participants who received bevacizumab with their induction chemotherapy will continue to receive bevacizumab on this study.
The purpose of this study is to determine safety and the maximum tolerated dose (MTD) of GRN163L and Velcade with and without Decadron when administered to patients with refractory or relapsed multiple myeloma.
The purpose of this study is to determine the maximum tolerated dose (MTD) of GRN163L in combination with paclitaxel and bevacizumab in patients with locally recurrent or metastatic breast cancer (MBC)
The purpose of this study is to determine the safety and the maximum tolerated dose (MTD) of GRN163L when administered to patients with refractory or relapsed multiple myeloma.
The purpose of this study is to determine the safety and the maximum tolerated dose (MTD) of GRN163L when administered in combination with a standard paclitaxel/carboplatin regimen to patients with advanced or metastatic non-small cell lung cancer.
The purpose of this study is to determine the safety and the maximum tolerated dose of GRN163L administration in treating patients with refractory or relapsed solid tumor malignancies.
The purpose of this study is to determine the safety and maximum tolerated dose of GRN163L in treating patients with refractory or relapsed chronic lymphoproliferative disease.
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 14, 2026 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gen … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 14, 2026 April 15, 2026 | 1 min read Twitter LinkedIn Facebook Email Print FOSTER CITY, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today r … rcial stage biopharmaceutical company, today reported that it granted an equity award in the form of a stock option to purchase 2,500,000 shares of Geron common stock to Timothy Williams, Geron’s new Executive Vice President, Chief Legal Officer and Corporate Secretary, as an inducement material to his acceptance of employment with Geron. The stock option was granted on April 13, 2026. The stock option has an exercise price of $1.73 per share, which is equal to the closing pr … 3 per share, which is equal to the closing price of Geron’s common stock on the grant date, has a ten-year term and vests over four years, with 12.5% of the shares underlying the option vesting on the six-month anniversary of commencement of his employment and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued service with Geron through the applicable vesting dates. The stock option grant was approved by the C … 635(c)(4) and is subject to the terms and conditions of Geron’s 2018 Inducement Award Plan and the form of stock option agreement under that plan. About Geron Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO ® (imetelstat) is approve
Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary April 13, 2026 | 5 min read Twitter LinkedIn Facebook Email Print Tim is a seasoned legal executive bringing extensive experience supporting commercial biopharmaceutical companies FOSTE … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Geron Corporation Names Harout Semerjian as New CEO to Lead Commercialization of RYTELO Home News Screener Charts Maps Groups Portfolio Insider Futures Forex Crypto Calendar Pricing Theme Help Login Register New Elite Feature: Personalize Your Finviz Homepage Learn More Market News Market Pulse Stocks News ETF News Crypto News Geron Corporation Names Harout Semerjian as New CEO to Lead Commercialization of RYTELO By Maham Fatima | August 17, 2025, 11:41 PM GERN +0.88% Geron Corp Geron Corporation (NASDAQ: GERN ) is one of the most promising penny stocks under $5 . On August 6, … 635(c)(4) GERN -7.14% GlobeNewswire Apr-14 Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GERN GlobeNewswire Apr-13 Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary GERN GlobeNewswire Apr-06 Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference GERN +5.42% GlobeNewswire Mar-26 Geron Announces Appointment of New Members to its Board of Directors GERN
Geron (GERN) names Harout Semerjian as CEO; 11M options granted | GERN 8-K Filing --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto … ormance target bonus 70% of base salary (prorated for 2025). Equity inducement: Grant of stock options to purchase 11,000,000 shares under the 2018 Inducement Award Plan; exercise price = Nasdaq closing price on start/grant date. Vesting: 7,000,000 options: 12.5% at six months then monthly over 42 months; 4,000,000 options: 25% at one year then monthly over 36 months; full vest upon Change in Control. Severance: Covered Termination: prorated target bonus, lump-sum equal to 18 … al to 150% of target bonus upon a qualifying Change of Control; 2018 Inducement Award Plan amended to add 11,000,000 shares for inducement grants. Exhibits: Employment Agreement (Exhibit 10.1), Amended Severance Plan (Exhibit 10.2), Amended 2018 Inducement Plan (Exhibit 10.3). Positive Experienced CEO appointment: Harout Semerjian brings commercial and hematology experience from Novartis, Ipsen and GlycoMimetics. Clear compensation terms: Base salary ($800,000), target bonus … ance provisions are disclosed. Retention and alignment: Large inducement option grant with multi-year vesting schedules and full vesting on Change in Control align long-term incentives. Formal plan amendments: Inducement award plan and severance plan changes are documented and filed as exhibits. Negative Potential dilution: Grant of 11,000,000 stock options and corresponding 11,000,000 share increase to the inducement plan increase potential share count and dilution. Generous … t and indemnification agreement. The filing discloses a large inducement option grant (11,000,000 shares) and amendments to the severance and inducement plans. Material governance points: (i) the option grant is expressly a Nasdaq Rule 5635(c)(4) inducement award and the inducement plan reserve is increased accordingly; (ii) the Amended Severance
Instagram Instagram Log In Sign Up Close Never miss a post from bcutd_newjersey Sign up for Instagram to stay in the loop. Sign up Log in bcutd_newjersey • Follow More options bcutd_newjersey Edited • 10w We are proud to announce that Harout Semerjian, President and CEO of Geron Corporation, will serve as the 2026 Corporate Walk Chair for the Morris County Light The Night. Harout has dedicated his career to advancing innovation in oncology and hematology, with a strong commitment to improving the lives of patients facing serious blood cancers. At Geron that mission includes shining light on lo
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Yahoo on osa Yahoo-konserni Sivustot ja sovellukset, jotka omistamme ja joita operoimme, mukaan lukien Yahoo ja Engadget, sekä digitaalinen mainospalvelumme (Yahoo Advertising). Yahoo-konsernia . Kun käytät sivustojamme ja sovelluksiamme, käytämme evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä tarjotaksemme sivustomme ja sovelluksemme sinul
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Yahoo on osa Yahoo-konserni Sivustot ja sovellukset, jotka omistamme ja joita operoimme, mukaan lukien Yahoo ja Engadget, sekä digitaalinen mainospalvelumme (Yahoo Advertising). Yahoo-konsernia . Kun käytät sivustojamme ja sovelluksiamme, käytämme evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä tarjotaksemme sivustomme ja sovelluksemme sinul
%PDF-1.3 %��������� 3 0 obj > stream x��k���q���W��(u��"���匬�HK�z,iף>sHӻ3�P����� $ tu͐ �0����r���� �_��ח��Ǐ>�/�Z��}���f�ѕ]_�z�����4MӠ�Om_uƩ� *�/ �������tuٍͩi� f��T�C����T7u;�؝Ft =�� G9H��"��53���d�h>`�O�� �ݘ� �&��r�� ���ȱan�As=bh����k��#8��e�l �� ����� �,i"I�,P �C�Y�y�e�h��QX�ԁI5OKՁ/@=,�2�=��U"4����.Q O�e�"�% ��(�rt{�a�ؑ���F��!ڶ�qC��:R!)���3�+H��5/�u=��h`��4�T��j�qSEMV9�h�NT:&v�$HH�D�BM�A����2��L%� Ti�+�V �� +�y�cĜjr]r 6!r��u���� ԁ����OȤ�:8�Ym�\3&��H�Z���Tx(Cn�3Ơǽ��` ��͑ �V |[�4����->(�`Ey�l �n� NR��IiZ��BC��c=�3���� q��w�� … �,�W��F�j_j*E�9�#3wK971DG�ѯȱp��I)zS�E��`�r�~e�jhШ�_�S�従��y��Ɏ��J�D�(��44���rfP�2�q^T#�� ���G�\D�� D�ڈb Ɉ �_�Ư���^@�цK�t��ѷ���U "De�pf��dB�~�̿��.�r�1�C�YC �"� �d� }��� �6�8.NnDеRW�p�VBs���[��0�@�QZC���(�/q�3m M�X�(~ �?t����-�wnG!ύTpH�{�F��.��5��͇�v����� �����@j�җ�t�N@��hy)�>(� � �g�Wj�_���-.�� !pM沲G�=r�j�4NgS � ��� ӌ�!�[7�ܹ�صA��e�e�N��rK�����a�E�^��TTI ��ZLB�-�v��0]��2��8�N�N��D5��c펗�� ��Ylv�� Ҝ�������97u ��Qzk@�k T�� ����*X �{8L�lm
Geron to present at ASCO and EHA on MF trials | Geron Corporation posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to
Geron Corporation Presentations at the American Association for Cancer Research 2008 Annual Meeting - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Geron Corporation Presentations at the American Association for Cancer Research 2008 Annual Meeting April 16, 2008 | 1 min read Twitter LinkedIn Facebook Email Print MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced five presentations of its anti-can … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
--> AACR 2017 Archives | Geron Skip to main content --> Your browser's JavaScript is disabled. To properly view the content on this page, please enable JavaScript. --> Research & Development Pipeline Telomerase Inhibition Clinical Trials Patients Information Stories Medicines Investors & Media Press Releases Events Stock Information Corporate Governance SEC Filings Analyst Coverage FAQs About Leadership Culture History Contact Partnering Responsibility Careers Publications AACR 2017 All Publications Telomerase inhibitor imetelstat in combination with the BCL-2 inhibitor venetoclax en … , selection for training opportunities, wage and salary administration, and the application of benefit plans and Company policies.
Instagram Instagram Log In Sign Up Close Never miss a post from creativereflection_ Sign up for Instagram to stay in the loop. Sign up Log in creativereflection_ and 3 others More options creativereflection_ Verified 47w congratulations to Ally & Geron - a Louisiana Saturday night with sips of sweet tea and lemonade. guests mingled over Italian ice and Chantilly cake while the magic of the night took over the dance floor. it was every bit of spectacular🥂 Ceremony | First Methodist Church | @firstmethodistshreveport Reception, Catering & Bar | East Ridge Country Club | @eastridgecountr
Geron to provide financial information at J.P.M. Healthcare conferefence - ImetelChat ImetelChat discussions on imetelstat and telomerase Skip to content Search Advanced search Quick links Unanswered topics Active topics Search Donations FAQ Login Register www.imetelstat.info Board index ImetelChat Search Geron to provide financial information at J.P.M. Healthcare conferefence Forum rules - Comments must be civil and on topic - Back up claims with evidence/reasoning/sources (posting links is allowed) - No commercials/harassment/spam Post Reply Print view Search Advanced search 4 posts • P
gern-20260112 false 0000886744 0000886744 2026-01-12 2026-01-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 12, 2026 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 919 E. HILLSDALE BLVD ., SUITE 250 FOSTER CITY , CA LIFORNIA 94404 (Address
Geron To Present At J.P. Morgan Healthcare Conference; Webcast At 11:00 AM ET Business Business Latest Headlines Top Stories Breaking News Earnings Biotech Investors Stock Alerts IPOs M&A Canadian UK Wallstreet Events Industry News Industry News Technology Software Banking Automotive Energy More Corp. Calendars Dividends Stock Splits Buybacks Conference Calls Earnings Calendar Earnings Calendar Pos Pre-announcements Profit Warnings Positive Surprise Negative Surprise Latest Earnings FDA Calendars Drug Approvals Clinical Trial Calendar Ratings Changes Upgrades Downgrades Cov Initiations Cov
Readout Newsletter: Geron, BIO, Eli Lilly, Vanda updates Skip to Main Content research NIH Cancer Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home News Latest Series & Investigations Business Biotech Pharma Health Tech Health Insurance Hospitals Medical Devices W … prices drug pricing FDA finance government agencies Pharmaceuticals research To submit a correction request, please visit our Contact Us page . Trending WHO director-general is profoundly concerned after visit to Ebola… WHO director-general is profoundly concerned after visit to Ebola outbreak area I’ve spent 40 years in research. I have never… I’ve spent 40 years in research. I have never seen a threat to science like the… Dexcom RCT suggests CGM benefit … o high response rate Politics Anil Oza STAT Plus: Scientists see promise in NIH proposal to cap number of grants they receive Exclusive Casey Ross and Bob Herman STAT Plus: Private Medicare plans erect barriers to rehab care in pursuit of profit, federal investigators find A decade of reporting from the frontiers of health and medicine Back to top Company About Our Team Contact Us Careers Diversity & Inclusion Awards Advertise With Us STAT Brand Studio Licensing Stories A
--> Working to change the course of blood cancers | Geron Skip to main content --> Your browser's JavaScript is disabled. To properly view the content on this page, please enable JavaScript. --> Research & Development Pipeline Telomerase Inhibition Clinical Trials Patients Information Stories Medicines Investors & Media Press Releases Events Stock Information Corporate Governance SEC Filings Analyst Coverage FAQs About Leadership Culture History Contact Partnering Responsibility Careers Our ambition is to change lives by changing the course of blood cancer. Powered by pioneering scie … , selection for training opportunities, wage and salary administration, and the application of benefit plans and Company policies.
We are proud to... - Blood Cancer United - New Jersey Facebook Вход Публикация Blood Cancer United - New Jersey Blood Cancer United - New Jersey 2 апрель · Поделился/-ась с Доступно всем We are proud to announce that Harout Semerjian, President and CEO of Geron Corporation, will serve as the 2026 Corporate Walk Chair for the Morris County Light The Night. Harout has dedicated his career to advancing innovation in oncology and hematology, with a strong commitment to improving the lives of patients facing serious blood cancers. At Geron that mission includes shining light on lower-risk myelodysp
gern-20250801 false 0000886744 0000886744 2025-08-01 2025-08-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2025 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 919 E. HILLSDALE BLVD ., SUITE 250 FOSTER CITY , CA LIFORNIA 94404 (Address of … salary, which will be prorated for 2025. In addition, the Company has agreed to grant Mr. Semerjian a stock option to purchase 11,000,000 shares of the Company’s common stock (the “Stock Options”) pursuant to the Company’s 2018 Inducement Award Plan (as defined below). The Stock Options will vest and become exercisable as follows: (i) 7,000,000 of the Stock Options will vest as to 12.5% of the shares underlying the grant on the six-month anniversary of … to 12.5% of the shares underlying the grant on the six-month anniversary of the grant date, with the remaining shares vesting in equal monthly installments over the following 42 months; and (ii) 4,000,000 of the Stock Options will vest as to 25% of the shares underlying the grant on the first anniversary of the grant date, with the remaining shares vesting in equal monthly installments over the following 36 months, in each case subject to Mr. Semerjian’s continued servi … t to Mr. Semerjian’s employment under the Company’s 2018 Inducement Award Plan and will have an exercise price equal to the closing price of the Company’s common stock on the Nasdaq Global Select Market on his start date, which will be the grant date. The Stock Options will fully vest upon the occurrence of a Change in Control (as defined in the Employment Agreement). Under the terms of the Employment Agreement, Mr. Semerjian is not eligible for an annual eq … of the Employment Agreement, Mr. Semerjian is not eligible for an annual equity award until 2027. The Employment Agreement also provides that Mr. Semerjian is entitled to severance benefits consistent with the Company’s other executive officers. In the event Mr. Semerjian’s employment is terminated due to a Covered Termination (as def
After a lackluster first drug launch, a new CEO is finding Geron’s commercial footing | PharmaVoice Skip to main content CONTINUE TO SITE ➞ Don't miss the most important voices in pharma Let PharmaVoice's free newsletter keep you informed on what industry leaders are saying, straight from your inbox. By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | BioPharma Dive Xtelligent Pharma Life Sciences Explore our brands An Informa TechTarget Publication Voices Q&A Profiles Biotech Spotlight First 90 Days O … mising treatment isn’t enough to guarantee success, even if it’s built on Nobel Prize-winning science . “When we launched our asset, the expectation of the market was one thing, and then our initial performance was not in line with the market expectation,” said Harout Semerjian, who took over as Geron’s president and CEO in August . Geron’s most recent financial results showed that Rytelo missed its revenue targets in the third quarter, just months after the company called fi
Harout Semerjian: A Visionary Leader Steering Geron Toward a New Era in Oncology - OncoDaily Calculators Oncologists OncoCalendar News Feed OncoDaily Pulse OncoGrants OncoDaily TV NewsLetter Voices Not To Miss FDA Approvals New Paper Alert OncoDaily 100 Community OncoDaily Magazine Career Updates Oncology Drugs Dialogues Stories Celebrities and Cancer Immune Oncology Breast Oncology Gastrointestinal Oncology Lung Oncology Hematology Radiotherapy Cancer Types Science Trial Updates ASCO ESMO ESO MASCC Cancer Center Near Me Oncologist Near Me OncoDaily Party 2025 Childhood Cancer Health Policy Ha … Blog Posts BIGR Global Cancer Movement History Oncolibrary OncoThon 2025 Yvonne Award 2025 Jun / 2026 June 2026 M T W T F S S 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 « May OncoDaily IO OncoDaily GI Hemostasis Today Fertility News Voices Not To Miss FDA Approvals New Paper Alert OncoDaily 100 Community OncoDaily Magazine Career Updates Oncology Drugs Dialogues Stories News Feed OncoDaily Pulse OncoGrants OncoD
--> Harout Semerjian | Geron Skip to main content --> Your browser's JavaScript is disabled. To properly view the content on this page, please enable JavaScript. --> Research & Development Pipeline Telomerase Inhibition Clinical Trials Patients Information Stories Medicines Investors & Media Press Releases Events Stock Information Corporate Governance SEC Filings Analyst Coverage FAQs About Leadership Culture History Contact Partnering Responsibility Careers Harout Semerjian President and Chief Executive Officer, Board of Directors Member Management Team Harout Semerjian has served a … , selection for training opportunities, wage and salary administration, and the application of benefit plans and Company policies.
EX-3.1 2 exhibit3-1.htm CERTIFICATE OF AMENDMENT OF THE RESTATED CERTIFICATE OF INCORPORATION EXHIBIT 3.1 CERTIFICATE OF AMENDMENT OF THE RESTATED CERTIFICATE OF INCORPORATION OF GERON CORPORATION, a Delaware corporation The undersigned, Stephen Rosenfield, hereby certifies that: FIRST. He is the duly elected and acting Executive Vice President, General Counsel and Corporate Secretary of Geron Corporation, a Delaware corporation (the “ Corporation ”). SECOND. The Corporation’s Restated Certificate of Inco
Excited to join Geron Corporation as EVP, Chief Legal Officer and Corporate Secretary! A differentiated therapy, a clear strategy, and a strong team - looking forward to helping drive the next phase… | Tim Williams | 50 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update yo
--> Our leadership team | Geron Skip to main content --> Your browser's JavaScript is disabled. To properly view the content on this page, please enable JavaScript. --> Research & Development Pipeline Telomerase Inhibition Clinical Trials Patients Information Stories Medicines Investors & Media Press Releases Events Stock Information Corporate Governance SEC Filings Analyst Coverage FAQs About Leadership Culture History Contact Partnering Responsibility Careers Our leadership With a seasoned leadership team with world-class expertise spanning research, clinical development, regulator … , selection for training opportunities, wage and salary administration, and the application of benefit plans and Company policies.
The objective of this expanded access protocol (EAP) is to provide access to treatment with imetelstat, the Investigational Product (IP), for eligible adult participants diagnosed with very low, low, intermediate risk (by Revised International Prognostic Scoring System, IPSS-R) myelodysplastic syndromes (MDS) who are red blood cell (RBC) transfusion-dependent, have failed to respond or have lost response or are ineligible for ESAs, had not received prior treatment with either a hypomethylating agent or lenalidomide and were non-del(5q), until such time that imetelstat becomes commercially available.